NeuroVigil is led by Dr. Philip Low, Founder, Chairman, and CEO.
Winner, Kavli Brain and Mind Innovative Research Award
Winner, Draper Fisher Jurvetson Venture Challenge
Winner, UCSD Entrepreneurship Challenge
Winner, CONNECT Most Innovative New Product in the Life Sciences
Winner, MIT Technology Review, MIT-TR35 Top Young Innovator under 35
Winner, Fast Company's Top 10 Most Innovative Companies in Health Care
Winner, Jacobs-Rady Pioneer Award for Global Innovation and Entrepreneurship
Winner, New York Times Magazine's 32 Innovations that Will Change Your Tomorrow
The Scientist Magazine's Scientist to Watch
He was appointed to dual positions at the Stanford School of Medicine and the MIT Media Lab in his twenties. His research collaborators include some of the World’s Top Pharma companies – the likes of Roche and Novartis – and his advisors include the late Stephen Hawking (at whose request NeuroVigil connected in 2013 a human to a computer non-invasively, on a single wireless channel, and enabled him to communicate with his mind, part of Dr. Low’s five dozen patents), Nobel laureates Dr. Roger Guillemin and the late Dr. Sydney Brenner, Wolfram Research’s Dr. Stephen Wolfram, IdeaLab’s Dr. Howard Morgan, Qualcomm’s Dr. Irwin Jacobs & Dr. Andrew Viterbi, SpaceX’s and Tesla’s Elon Musk, as well as Laurene Powell Jobs who is advising him personally. He created and chaired the first international Congress on Alzheimer’s & Advanced Neurotechnologies and the Francis Crick Memorial Conference on Consciousness. He has advised the Obama White House, the US Congress, NASA (Chief Scientist for Human Space Program), the US Armed Forces (Chief of Naval Operations), and the Israeli, Canadian and Argentine governments on Neurotech. He is an advisor to the Jonas Salk Legacy Foundation and a board member of the MacArthur Foundation prize-winning Recipe For Change Foundation, which provides non-violent offenders cooking and art skills to maximize their chances of successfully reintegrating the work force.
Dr. Low’s honors include the MIT TR-35 Top Young Innovator Award (worldwide), the DFJ Venture Challenge and the inaugural Jacobs-Rady Pioneer Award for Global Innovation & Entrepreneurship. His inventions and discoveries have been profiled in scientific and popular media including Science, PNAS, CNN, TIME, Newsweek, Forbes, the Economist, the Washington Post which lists NeuroVigil as one of the “Top 10 Most Innovative Companies in Health Care”, The Scientist which singled out Dr. Low as “A Scientist to Watch” and the New York Times which has recognized iBrain as “an innovation that will change your tomorrow.”
Mr. Paul Kreutz has practiced law since 1967. He started his practice in the San Francisco Bay Area with the law firm of Cooley Godward and in 1969 joined the Palo Alto firm of Ware & Freidenrich, one of Silicon Valley’s pre-eminent law firms. When Ware & Freidenrich joined with San Diego’s Gray Cary in 1994, Mr. Kreutz relocated to San Diego to build the combined firm’s emerging company practice (now known as DLA Piper) in Southern California which he served as senior partner until his launch in 2007 of a boutique solo practice that offers emerging companies in Southern California the mentoring, strategic legal counseling skills, and the financial networking connections that he has acquired in his many years of practice.
Mr. Kreutz’s practice has focused on emerging companies with an emphasis on counseling and structuring entrepreneurial enterprises poised for growth. He has served as legal counsel for such companies as Adobe Systems, 3Com Corporation, Bay Networks, KLA Instruments (now KLA-Tencor), Ross Stores, and McAfee Associates. In most of these cases, Mr. Kreutz counseled these companies from startup, through multiple rounds of private financings, to successful public offerings. He has acted as legal counsel for many of the Bay Area’s pre-eminent Venture Capital firms including the representation of Sequoia Capital in its investment in Cisco Systems and TA Associates in its investment in BMC Software. In Southern California, Mr. Kreutz has represented Enterprise Partners, Forward Ventures, and many other Southern California venture capital firms.
As legal counsel for emerging companies, Mr. Kreutz is regularly called upon to advise Boards of Directors, officers, and shareholders as to their corporate responsibilities under circumstances where the interests of the directors, officers and shareholders may not be aligned with such corporate interests. Mr. Kreutz is a graduate of Yale University (BA 1964 cum laude) and Stanford Law School (LLB 1967).
Mr. Kreutz executed NeuroVigil’s historic seed and Series A financings and serves as NeuroVigil’s General Counsel.
Sources: Paul E. Kreutz & NeuroVigil.
Dr. Lisa Haile Dr. Lisa Haile, JD, PhD, is a Partner and Co-Chair of DLA Piper's Global Life Sciences Sector. Dr. Haile has special technical experience in molecular biology, immunology, cell biology, regenerative medicine including ESCs, iPSCs, pSCs, diagnostics, therapeutics, theragnostic, drug delivery systems, host-vector systems, high throughput screening and bioinformatics. She has experience with patentability, non-infringement and validity opinions; licensing strategies; FDA counseling; due diligence work in connection with venture capital, private and public financing; mergers and acquisitions in the life sciences industry; and strategic counseling for comprehensive life sciences patent portfolio management. Dr.Haile and her team oversee prosecution of NeuroVigil’s growing patent portfolio and has successfully obtained protection of industry-defining patents in several key markets. Ms. Haile is a graduate of California Western School of Law (JD 1991) and has a PhD in Microbiology and Immunology from Georgetown University School of Medicine (Ph.D. 1987).
Dr. Haile is a member of DLA Piper's Executive Committee.
Souces: DLA Piper, LLP & NeuroVigil.
Mr. Jeffrey N. Gibbs has represented health care companies on FDA-related matters since 1984. He advises companies on a wide variety of issues, including product approvals, marketing, clinical studies, and enforcement. Previously, he served in the Chief Counsel's Office of the U.S. Food and Drug Administration, where he became an Associate Chief Counsel for Enforcement. While at FDA, Mr. Gibbs received the FDA Award of Merit. He also was appointed a Special Assistant United States Attorney for the District of Columbia. Before joining FDA, he clerked for a United States District Court Judge in the District of New Jersey. Mr. Gibbs has written and lectured extensively on a variety of FDA-related topics. Mr. Gibbs served as a member of the Editorial Advisory Board for the Food and Drug Law Journal from 1998 to 2004, and was Chair in 2003-2004. He is currently on the editorial advisory board of IVD Technology and Guide to Good Clinical Practices, and is a member of the Human Subjects Research Board for George Mason University. Mr. Gibbs serves as Secretary and General Counsel of the Board of Directors of the Food and Drug Law Institute. He is a graduate of Princeton University (1975 summa cum laude) and the New York University School of Law (1978 with honors). He is admitted to practice law in the District of Columbia. Source: Hyman, Phelps & McNamara, LLP
NeuroVigil has other highly experienced attorneys on staff for Corporate, Litigation and IP matters.